LYPLAL1酶活性与肝脏葡萄糖代谢有关
Roxana Filip1, Étienne Bélanger1, Xinhzu Chen1
1Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, K1N 6N5, Canada.
Biochemical and biophysical research communications
|March 27, 2025
概括
血清酶LYPLAL1通过抑制葡萄糖生成和促进糖分解来调节葡萄糖代谢,其活性由代谢应激和胰岛素信号调节.
科学领域:
- 生物化学 生物化学
- 代谢途径 代谢途径
- 酶学 是一种酶学.
背景情况:
- 血清酶LYPLAL1 (lysophospholipid acyltransferase 1) 与肝脏代谢有关,其中的基因变异与肥胖和胰岛素抵抗有关.
- 它在肝脏新陈代谢中的确切功能在很大程度上仍未被描述,尽管有证据表明它在葡萄糖平衡中的作用.
研究的目的:
- 通过选择性基于活动的探针来研究Lypal1在肝脏代谢中的特定作用.
- 阐明LYPLAL1在代谢压力和荷尔蒙控制下的活性调节.
主要方法:
- 利用基于活动的选择性探针来监测肝细胞中的LYPLAL1酶活性.
- 进行基因淘汰试验,以评估 LYPLAL1 对肝脂质概况的影响.
- 研究了LYPLAL1在HepG2细胞中的胰岛素介导调节及其对胰岛素和葡萄糖治疗的反应.
主要成果:
- 在代谢压力期间,LYPLAL1的活动受到调节,这表明它在负调节葡萄糖生成和上调调节葡萄糖分解方面发挥了作用.
- LYPLAL1的淘汰赛并没有显著改变肝脂质概况.
- 有证据表明,对LYPLAL1活性进行胰岛素介导的控制,活性是经过翻译调节的,而不是取决于基因表达水平.
结论:
- LYPLAL1在调节肝脏葡萄糖代谢方面发挥着重要作用,可能在信号传导中起到反机制的作用.
- 它的活性由代谢状态和荷尔蒙线索动态调节,独立于基因表达的显著变化.
相关概念视频
Cell Specific Gene Expression
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Liver Physiology
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...


